Compare BioNano Genomics Inc (BNGO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs RLX Technology Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 177.2× BioNano Genomics Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | RLX | |
|---|---|---|
Market Cap | $13.66M | $2.42B |
Sector | Health | Technology |
52-Week High | $4.92 | $2.73 |
52-Week Low | $1.06 | $1.79 |
Enterprise Value | $16.26M | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
RLX Technology trades at $2.02, up 1.0% today, amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 22.47% net margins and solid cash flow generation, though recent quarterly earnings have missed expectations. International expansion remains a key growth driver, with overseas revenue now exceeding 70% of total sales following the Totally Wicked acquisition.
While RLX maintains strong fundamentals and cash reserves, the bearish technical outlook and recent earnings misses create near-term uncertainty. The company's international growth strategy offers potential upside, but regulatory risks in the vaping industry and execution challenges pose significant headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
